News By Tag
News By Location
Nemucore Announces Publication in Pharmaceutical Research
Platinum-based chemotherapy is the treatment of choice for malignant epithelial ovarian cancers, but generalized toxicity and platinum resistance limits its use in heavily treated patients. Nemucore has designed a novel molecularly targeted theranostic to overcome these limitations. The therapy specifically targets epidermal growth factor receptor (EGFR), a cell-surface receptor overexpressed in certain ovarian cancers, to selectively deliver a highly effective platinum payload. EGFR overexpression in cancer is implicated in high disease aggressiveness and drug resistance.
The data outlined in the publication demonstrated that significantly more of Nemucore’s targeted theranostic accumulates in tumors expressing EGFR versus a non-targeted theranostic. The data supports the use of targeted theranostic agents in conjunction with magnetic resonance imaging (MRI) to image disease loci and provide longitudinal pharmacodynamic results. Nemucore’s targeted therapeutic also exhibited less toxicity and enhanced the survival time of mice as compared to an equivalent cisplatin treatment. MRI data indicates that the targeted theranostic is an effective contrast agent and could be used to track accumulation in a tumor.
"This publication provides compelling evidence that molecularly targeted theranostics could play a major role in the care of patients with multidrug resistant cancers," said Nemucore’s CEO Timothy Coleman, Ph.D. "These molecularly targeted theranostics have unique characteristics that overcome the barriers associated with ineffective drug delivery to complex diseases such as ovarian cancer."
About Nemucore Medical Innovations, Inc.
Nemucore is dedicated to designing, investigating, developing, and commercializing life-saving novel therapeutics for the treatment of ovarian cancer and other unmet medical needs. Ultimately, Nemucore’s products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. Nemucore was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit http://www.nemucore.com.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.